The Resistance of Cancer Cells to Palbociclib, a Cyclin-Dependent Kinase 4/6 Inhibitor, is Mediated by the ABCB1 Transporter

• Main Authors: Han Fu (Author), Zhuo-Xun Wu (Author), Zi-Ning Lei (Author), Qiu-Xu Teng (Author), Yuqi Yang (Author), Charles R. Ashby (Author), Yixiong Lei (Author), Yuyin Lian (Author), Zhe-Sheng Chen (Author)
• Format: Book
• Published: Frontiers Media S.A., 2022-03-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Palbociclib was approved by the United States Food and Drug Administration for use, in combination with letrozole, as a first-line treatment for estrogen receptor-positive/human epidermal growth factor receptor 2-negative (ER+/HER2-) postmenopausal metastatic breast cancer. However, recent studies s...